Seneca Biopharma Inc.Find Ratings Reports
SENECA BIOPHARMA INC's gross profit margin for the first quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. SENECA BIOPHARMA INC is extremely liquid. Currently, the Quick Ratio is 8.47 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 204.95% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY20||Q1 FY19|
|Net Sales ($mil)||0.01||0.0|
|Net Income ($mil)||-7.58||-3.11|
|Balance Sheet||Q1 FY20||Q1 FY19|
|Cash & Equiv. ($mil)||10.03||4.01|
|Total Assets ($mil)||11.36||5.41|
|Total Debt ($mil)||0.17||0.05|
|Profitability||Q1 FY20||Q1 FY19|
|Gross Profit Margin||-32683.33||-80533.33|
|Return on Assets||-112.78||-109.0|
|Return on Equity||-128.41||-180.1|
|Debt||Q1 FY20||Q1 FY19|
|Share Data||Q1 FY20||Q1 FY19|
|Shares outstanding (mil)||9.43||0.91|
|Div / share||0.0||0.0|
|Book value / share||1.06||3.59|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||3072741.0||1854071.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 0.69 indicates a significant discount versus the S&P 500 average of 3.33 and a significant discount versus the subsector average of 10.18. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, SENECA BIOPHARMA INC proves to trade at a discount to investment alternatives.
|SNCA NM||Peers 34.58||SNCA NM||Peers 47.01|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SNCA's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SNCA's P/CF is negative making the measure meaningless.
|SNCA NA||Peers 34.73||SNCA NA||Peers 0.82|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SNCA 0.69||Peers 10.18||SNCA 50.86||Peers 8.04|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SNCA is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
SNCA is expected to have an earnings growth rate that significantly exceeds its peers.
|SNCA 344.12||Peers 545.31||SNCA -93.08||Peers 148.39|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SNCA is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
SNCA significantly trails its peers on the basis of sales growth.